Journal
NATURE REVIEWS CANCER
Volume 18, Issue 3, Pages 139-147Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrc.2017.117
Keywords
-
Categories
Funding
- National Cancer Institute [K99/R00CA204595]
- American Cancer Society-Jules L. Plangere Jr. Family Foundation Professorship in Cancer Immunotherapy
- [R35 CA210098]
Ask authors/readers for more resources
Immunotherapeutic interventions are showing effectiveness across a wide range of cancer types, but only a subset of patients shows clinical response to therapy. Responsiveness to checkpoint blockade immunotherapy is favoured by the presence of a local, CD8(+) T cell-based immune response within the tumour microenvironment. As molecular analyses of tumours containing or lacking a productive CD8(+) T cell infiltrate are being pursued, increasing evidence is indicating that activation of oncogenic pathways in tumour cells can impair induction or execution of a local antitumour immune response. This Review summarizes our current knowledge of the influence of oncogenic effects on evasion of antitumour immunity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available